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1. Summary 
1.1. Summary 
Campylobacteriosis is an emerging foodborne enteric disease in humans worldwide. Poultry 
meat is an important source of infection. One strategy in the combat against Campylobacter at 
production level is the vaccination of broiler chickens. In this study, a Salmonella enterica 
subsp. enterica serovar Typhimurium (S. Typhimurium) strain was modified and used as a 
vector to express the N-glycan from Campylobacter on its surface. The immunogenicity of 
this live vaccine was tested per os in 70 commercial broilers. The vaccine was able to 
colonize broilers without causing disease. No detectable humoral immune response and no 
reduction of colonization of C. jejuni in the caeca was observed due to vaccination, however 
the chickens produced antibodies against the Campylobacter N-glycan upon infection with the 
Campylobacter jejuni challenge strain. 
 
Keywords: Campylobacter N-glycan, live-attenuated Salmonella Typhimurium vaccine, 
humoral immune response, broiler chickens  
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1.2. Zusammenfassung 
Die Campylobacteriose des Menschen ist eine weltweit vorkommende, 
lebensmittel-assozierte gastrointestinale Erkrankung. Der Einsatz eines geeigneten 
Impfstoffes ist eine mögliche Strategie, um die Campylobacter-Besiedlung des Mastgeflügels 
zu reduzieren. In dieser Studie wurde als Vektor Salmonella enterica subsp. enterica serovar 
Typhimurium (S. Typhimurium) verwendet, welche das Campylobacter N-Glykan als 
spezifisches Antigen auf der Oberfläche präsentiert. Dieser Lebendimpfstoff wurde 
kommerziellen Masttieren per oral verabreicht und die Immunogenität und die Verträglichkeit 
getestet. Der Impfvektor konnte die Blinddärme der Masttiere kolonisieren, ohne eine 
Erkrankung hervorzurufen. Die Impfung induzierte indes keine humorale Immunantwort 
gegen das präsentierte Campylobacter Antigen und führte auch zu keiner Reduktion der 
C. jejuni Kolonisation in den Blinddärmen der Versuchsbroiler. Die Infektion mit C. jejuni in 
den Challenge Experimenten führte jedoch wie bei einer natürlichen Campylobacter Infektion 
zu einer erworbenen humoralen Immunantwort gegen das Campylobacter N-Glykan. 
 
Stichworte: attenuierter Salmonella Typhimurium Lebendimpfstoff, Mastgeflügel, 
Campylobacter N-Glykan, humorale Immunantwort 
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2. Introduction 
Campylobacter jejuni (C. jejuni) and the closely related Campylobacter coli (C. coli) are 
thermophilic gram-negative bacteria. They belong to the most important zoonotic agents 
causing foodborne illness in humans worldwide (Allos 2001, Janssen et al. 2008, Dasti et al. 
2010). In Europe, Campylobacter is the most reported foodborne pathogen followed by 
Salmonella. In 2009, 45.6 per 100 000 population confirmed campylobacteriosis cases were 
reported in Europe (EFSA 2011). 
 
Thermophilic Campylobacter spp. are ubiquitous in the environment and colonize the 
alimentary tract of wild and domestic animals as a commensal organism (Newell and 
Fearnley 2003). Wild birds and chickens are a natural C. jejuni / C. coli reservoir (Newell and 
Fearnley 2003, Janssen et al. 2008, Dasti et al. 2010). The bacteria are primarily found in the 
mucus covering the epithelia of the caeca and the small intestine (Newell and Fearnley 2003). 
In general, chickens become colonized the earliest at 10 days of age, and most flocks become 
infected at the age of two or three weeks. This persistent negative delay of colonization is 
referred to as lag-phase (Newell and Fearnley 2003, Cawthraw and Newell 2010). Chicken 
colonization proceeds without clinical symptoms, even when a high infective dose is given 
(Wyszynska et al. 2004). Nevertheless, Welkos et al. (1984) observed that newly hatched 
chickens developed enteritis after oral gavage of a C. jejuni strain within the first hours. In 
animal experiments, the infective dose was found to be lower than 40 colony forming units 
(cfu) of C. jejuni, and up to 10
9
 cfu per gram caecal contents could be detected in 
experimentally challenged birds after colonization (Newell and Fearnley 2003, Dasti et al. 
2010, Welkos et al. 1984). Bird to bird transmission occurs rapidly. Once the bacterium is 
introduced into a flock up to 100 percent of the chickens are colonized after a few days due to 
coprophagy (Brendtson et al. 1996, Newell and Fearnley 2003).  
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Campylobacter is highly infectious for humans and a very low infective dose of 500 to 800 
cfu has been reported (Janssen et al. 2008). Handling of contaminated poultry products and 
eating of undercooked poultry meat is an important source of sporadic Campylobacter 
infection (Harris et al. 1986, Butzler and Oosterom 1991, EFSA Journal 2010). Sources of 
massive outbreaks of infection are contaminated drinking water or milk (Butzler and 
Oosterom 1991, Harris et al. 1986, Janssen et al. 2008, EFSA Journal 2010). 
Campylobacteriosis is further a frequently reported disease of travellers (Büttner and Jost 
2011). Usually, Campylobacter infection results in a self-limiting disease presenting clinical 
symptoms of an acute gastroenteritis characterized by watery or blood-tinged diarrhoea, 
nausea, abdominal pain and fever (Butzler and Oosterom 1991, Janssen et al. 2008). 
Nevertheless, a known post-infectious complication due to Campylobacter infection is an 
autoimmune disorder named Guillain-Barré syndrome (GBS) (Hughes et al. 1999). 
Because contaminated poultry meat represents a high risk for Campylobacter infection 
(Harris et al. 1986, Butzler and Oosterom 1991, EFSA 2010, Büttner and Jost 2011), 
industrialized countries attempt to achieve reduction or even elimination of these bacteria in 
the food chain (Newell and Fearnley 2003, EFSA 2011). Intervention can be made at 
production level, in the abattoir, and at the consumer level. One strategy at production level is 
to prevent broiler chickens from being colonized by Campylobacter in the first place (Newell 
et al. 2011, Pasquali et al. 2011, EFSA 2011, Rice et al. 1997). For example, this was 
achieved with the Salmonella eradication in Swiss flocks. In a Danish study (Hald et al. 
2007), it was demonstrated that fly screens significantly reduce Campylobacter occurrence in 
broiler houses. However, this measure is not feasible in all husbandry systems. Contamination 
or cross-contamination of carcasses can be targeted in the abattoir with chemical or physical 
methods (EFSA 2011). The cross-contamination in the consumer’s kitchen is also an 
important risk factor. Contamination occurs by way of direct contact of raw meat or meat 
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juice with products that are eaten uncooked or by indirect path, e.g. via work surface, hands or 
cooking utensils (Jacobs-Reitsma et al. 2008, EFSA 2010). 
 
One of the most promising and effective strategies to avoid Campylobacter colonization in 
chickens is to vaccinate against these commensal bacteria. De Zoete et al. (2007) mentioned 
that vaccination of chickens against Campylobacter bears the challenge of identifying a 
cross-protective antigen, which is able to induce an early and potent immune response.  
Many efforts have already been taken in production of vaccines, however with limited success 
(as summarized in De Zoete et al. 2007). In one study, mice were orally vaccinated with 
heat-killed Campylobacter in combination with heat-labile enterotoxin (LT) from 
Escherichia coli. These mice developed a protection against Campylobacter infection and 
elicited a secretory IgA (sIgA) immune response against particular Campylobacter antigens 
(Rollwagen et al. 1993, Baqar et al. 1995). A similar vaccine experiment was done with 
broiler chicks. Birds received formalin inactivated C. jejuni with or without E. coli LT per os. 
A reduction of the caecal load of C. jejuni compared with the non-vaccinated control was 
reported and further development of an orally applicable vaccine was recommended (Rice et 
al. 1997). 
Attenuated Salmonella spp. mutants are recognized as outstanding organisms to generate a 
live recombinant vaccine, which can achieve a mucosal immunization in the vaccinated 
livestock (Kotton and Hohmann 2004). An avirulent Salmonella carrying the C. jejuni 
72Dz/92 cjaA gene was used for a vaccine study, demonstrating a reduction of C. jejuni in the 
caeca of the birds in protection experiments (Wyszynska et al. 2004). Layton et al. (2011) 
used an attenuated Salmonella vector expressing three peptide epitopes from Campylobacter 
proteins on the surface, and demonstrated a reduction of the Campylobacter load in the ileum. 
Not only proteins may be used as antigens. In the search for new cross-protective antigens for 
vaccine development, oligosaccharide molecules offer a new, promising approach.  
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O- or N-linked protein glycosylation in eukaryotes is a universal posttranslational 
modification and influences protein functions, e.g. stabilisation of the native state, immune 
response modulation and solubility enhancement (Helenius and Aebi 2004, Szymanski and 
Wren 2005, Nothaft and Szymanski 2010). The newly discovered prokaryotic N-linked 
protein glycosylation pathway was first described in C. jejuni and is now well characterized 
(Linton et al. 2005, Wacker et al. 2002, Young et al. 2002). The genes located on the 16 kb 
long pgl loci, are responsible for the posttranslational modifications of over 65 periplasmatic 
and surface proteins (Wyszynska et al. 2008, Szymanski and Wren 2005, Nothaft and 
Szymanski 2010). N-linked glycosylated proteins in Campylobacter are known to be highly 
immunogenic in humans (Szymanski et al. 1999, Hermans et al. 2011). Wacker et al. (2002) 
demonstrated that the pgl operon from C. jejuni could be transferred into E. coli, which is 
subsequently able to produce N-linked glycoproteins. These E. coli strains are designated 
“glycosylation competent” (pgl+) E. coli and are particularly useful in glycoengineering. 
Glycoengeneering aims at producing glycosylated proteins in high purity and of considerable 
yield, as shown by Lizak et al. 2011, who used pgl+ E. coli to glycosylate and produce the 
murine single-chain variable fragment (scFv) from anti-His tag antibody 3D5 (characterised 
and engineered by Kaufmann et al. 2002). 
Little is known about the biological significance of protein glycosylation in bacteria. 
However, a chicken colonization study with a Campylobacter pglH (transferase) mutant 
showed reduced ability of the mutant to colonize chickens (Karlyshev et al. 2004). Mutants in 
the N-linked pgl system further lead to changes in protein antigenicity, reduced cell invasion 
and reduced capacity to colonize the intestinal tract of mice and chickens (Szymanski et al. 
2002, Szymanski et al. 2003, Larsen et al. 2004) 
 
The building blocks of the C. jejuni glycan are N-acetylgalactosamine (GalNAc), glucose 
(Glc) and bacillosamine (Bac; 2,4-diacetamido-2,4,6-trideoxy-glucopyranose) (Szymanski et 
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al. 1999, Young et al. 2002, Szymanski and Wren 2005) The assembled C. jejuni 
heptasaccharide consists of Bac-GalNAc5-Gluc (Table 2), with a bacillosamine at its reducing 
end (Young et al. 2002). This entity was chosen as candidate antigen for a vaccine in broilers 
because it is highly conserved in Campylobacter (Szymanski and Wren 2005) and is therefore 
thought to elicit a good cross-protectivity. Vaccination in broiler chicken should be broad 
concerning Campylobacter species (De Zoete et al. 2007), because vaccinating against one 
species may open a niche for another. As immunogenicity of this specific Campylobacter 
N-glycan was proven in sera from humans and mice, the use of this antigen is very promising 
(Szymanski et al. 1999, Ilg 2009). 
 
As a prerequisite to our study, a newly engineered Salmonella enterica subsp. enterica 
serovar Typhimurium (S. Typhimurium) vector strain was constructed. To understand how 
this Salmonella was tweaked to highly express Campylobacter-heptasaccharide, we first have 
to briefly get acquainted to the biosynthesis of glycolipids in Salmonella and secondly to the 
Campylobacter N-glycan pathway. 
Like all Gram-negative bacteria, a wild type S. Typhimurium has an inner and an outer 
membrane. Within the family Enterobacteriaceae, the outer membrane carries the 
lipopolysaccharides (LPS) and the enterobacterial common antigen (ECA). LPS consists of a 
lipid A core, non-repetitive oligosaccharide and a repetitive polysaccharide, the latter being 
species-specific and commonly known as O-antigen (Raetz und Whitfield 2002, Murray et al. 
2003). The O-antigen together with the H-antigen of the flagellum forms the basis of 
Salmonella serotyping, according to the White-Kauffmann-Le Minor scheme (Grimont and 
Weill 2007). Salmonella with LPS show a smooth (S) phenotype when cultured on agar 
plates, while LPS-lacking Salmonella show a so-called rough (R) phenotype, that is 
recognized by flatter, rougher colonies with frayed margins. Not all steps in the assembly of 
LPS in Salmonella and its shuttling to the surface of the outer membrane are understood. The 
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current hypothesis is that the lipid A core is synthesized in the cytoplasm, shuttled to the outer 
membrane, and anchored in the outer membrane. The variable part of the LPS is assembled in 
the cytoplasm and initially processed by the WbaP transferase, transported through the inner 
membrane by a Wxz-dependent mechanism and polymerized by Wzy. Wxz is thus 
colloquially known as “O-antigen flippase” (Liu et al. 1996). ECA is an outer membrane 
glycolipid produced by all Enterobacteriaceae (Makela and Mayer 1976). ECALPS uses a 
pathway initiated by the transferase WecA to be attached to a lipid A core in the outer 
membrane. 
For N-linkage of different proteins in Campylobacter, the heptasaccharide is assembled on a 
lipid carrier in the inner cell membrane (undecaprenyl pyrophosphate), shuttled through the 
inner membrane by the ATP binding cassette (ABC) transporter PglK and attached to its 
acceptor proteins by the PglB oligosaccharide transferase (Feldman et al. 2005, Szymanski et 
al. 2003). 
 
The S. Typhimurium O-antigen ligase WaaL, which transfers the polymerised O-antigen to 
the lipid A core, shows relaxed saccharide substrate specificity (Falt et al. 1996, Wang et al. 
1999, Xu de et al. 2007). Thus it is possible to engineer a Salmonella linking a 
Campylobacter N-glycan to the lipid A core on its surface. For this, an O-antigen negative 
derivate of the S. Typhimurium SL1344 (a human isolate by Hoiseth and Stocker 1981) 
termed SL1344ΔwbaP (SKI12) (Ilg et al. 2009) could be transformed with a plasmid 
containing a modified C. jejuni pgl cluster (termed pgl3mut), where N-acetylglucosamine 
(GlucNAc) gets incorporated into the heptasaccharide instead of bacillosamine. Additionally, 
pgl3mut contains an inactive oligosaccharyltransferase PglB. This construct results in an 
O-antigen negative S. Typhimurium displaying the C. jejuni heptasccharide, with a GlucNAc 
instead of a bacillosamine at the reducing end. This GlucNAc at the reducing end is 
introduced due to enhanced acceptor activity of WecA, as ECA assembly also occurs on 
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undecaprenylpyrophosphate, the carrier of the N-glycan. This leads to a high amount of the 
antigen displayed on the Salmonella surface (Ilg 2009).  
 
To test the immunogenicity of the modified C. jejuni heptasaccharide presented by the 
S. Typhimurium SKI12, three 6-9 weeks old female C57BL/6 mice were injected 
intravenously with the heat-inactivated SKI12. One of three mice showed specific anti 
Campylobacter N-glycan IgG in immunoblot analysis (Ilg 2009). 
In order to be used in this study with chickens, minor changes were performed on the 
S. Typhimurium strain SKI12, precise integration of the pgl-operon into the genome was 
performed. The resulting strain was named SKI40. A corresponding strain, harbouring the 
vector control, lacking the pgl insert, was constructed and named SKI41. Note that the 
phenotype of SKI40 and SKI41 is a R-form, because it is devoid of the O-antigen.  
 
In this study we tested whether S. Typhimurium SKI40, presenting the 
Campylobacter-heptasaccharide on its surface, is a suitable candidate for a vaccine against 
Campylobacter in broiler chickens. We wanted to address the following points: (i) evaluate 
the attenuation of the Salmonella vector in an avian species, (ii) test the stability of the 
pgl3mut in vivo, (iii) have insight into the humoral immune response against entire and 
truncated forms of the Campylobacter-heptasaccharide and the Salmonella backbone in 
vaccinated chickens and (iv) measure whether the vaccine leads to reduction in 
Campylobacter colonization of the caeca. 
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3. Materials and Methods 
3.1. Bacteriology 
3.1.1. Bacterial strains 
An overview of bacterial strains used in this study is given in Table 1. 
 
3.1.2. Salmonella detection by culture 
Qualitative detection in animal faeces, organs and environmental samples was carried out 
according to EU 2002. Briefly, samples were incubated in buffered peptone water (“Buffered 
Peptone Water (ISO)” (BPW), CM1049; Oxoid, Wesel, Germany) for 24 h at 37 °C, 
subcultivated onto modified semi-solid Rappaport Vassiliadis medium (“MSRV Medium 
Base, modified”, 1.09878.0500, “MSRV Selective supplement”, 1.09874.0001, Merck, 
Darmstadt, Germany) and incubated at 41.5 °C for 18 h. Suspected swarming halos were 
subcultivated onto xylose lysine deoxycholate agar plates (43563, BioMérieux, Mary 
L’Etoile, France). Salmonella Typhimurium colonies of either SKI40 or SKI41 were 
recognizable by their rough texture, as these strains are devoid of the O-antigen. Colonies 
were confirmed with S. Typhimurium specific real-time PCR. 
Enumeration of the vaccine strains S. Typhimurium SKI40 and SKI41 in caecal contents of 
experimentally vaccinated chickens was performed by serial dilution in sterile, physiological 
sodium chloride solution and then plated in duplicates on Luria-Bertani (LB) agar (244520, 
Difco Laboratories, Detroit, MI, U.S.A) plates containing streptomycin (final concentration: 
50 µg/ml, A1852, AppliChem, Darmstadt, Germany), tetracycline (final concentration: 
10 µg/ml, A2228, AppliChem) and ampicillin (final concentration: 100 µg/ml, A0839, 
AppliChem). This agar medium will be designated LB-STA agar throughout the text. 
Stability testing of the pBRpgl3mut plasmid of SKI40, and the pBR322 plasmid of SKI41, 
which both carry an ampicillin resistance (Table 1), was performed using caecal content taken 
after necropsy. Serial 10-fold dilutions of faecal samples were cultured on LB-STA and on 
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LB agar containing only streptomycin (final concentration: 50 µg/ml) and tetracycline (final 
concentration: 10 µg/ml), designated LB-ST agar.  
 
3.1.3. Campylobacter detection by culture 
Campylobacter detection and enumeration was modified from EU 2006. Briefly, 500 µl 
sterile sodium chloride suspension containing 50 ng caecal contents was prepared. 50 µl of 
the serial dilution was plated in duplicates on Brilliance
TM
 CampyCount agar plates (PO 
5305A, Oxoid) and incubated at 42 °C under microaerobic conditions (5 % O2, 5 % CO2, 
80 % N2, and 10 % H2) for 48 h. Confirmation was done by specific C. jejuni real-time PCR. 
 
3.1.4. Production of the vaccine dose 
Frozen stock cultures of Salmonella Typhimurium strains SKI40 and SKI41 were 
reconstituted on Columbia agar with 7 % sheep blood (COL SB, PB 5008A, Oxoid, Wesel, 
Germany) and incubated aerobically at 37 °C for 24 hours, before streaking onto LB-STA 
agar plates. One single colony was picked and resuspended in Luria-Bertani (LB) broth 
(244620, Difco Laboratories, Detroit, Mich.) containing streptomycin, tetracycline and 
ampicillin respectively (LB-STA broth). Same final concentrations of the antibiotics were 
used as described above (see 3.1.2. Salmonella detection by culture). The culture was 
incubated aerobically at 37 °C in a shaking incubator. After 12 h of growth a subculture was 
produced by suspending 100 µl of the overnight culture in 2 ml LB-STA broth. This 
subculture was incubated for 4 h aerobically at 37 °C in a shaking incubator. 500 µl of this 
subculture was centrifuged and the pellet resolved in 500 µl sterile phosphate-buffered saline 
(PBS). Each animal received 50 µl of the cell suspension diluted in 150 µl sterile PBS by oral 
gavage. The administered vaccine dose was determined by serial dilution on LB-STA agar 
plates and aerobic incubation at 37 °C for 12 h.  
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3.1.5. Production of the challenge dose 
C. jejuni CC21 ST21, from a frozen stock, was streaked onto COL SB agar (PB 5008A, 
Oxoid, Wesel, Germany) incubated for 24 hours at 42 °C and subcultured twice for 18 h 
under microaerobic conditions (5 % O2, 5 % CO2, 80 % N2, and 10 % H2). Two loops of 
C. jejuni CC21 ST21 were picked and suspended in 5 ml sterile PBS. The suspension was 
diluted to an OD600 of 0.43 measured with an Eppendorf BioPhotometer (6131 000.039, 
Eppendorf, Hamburg, Germany). Each animal received 100 µl of the cell suspension by oral 
gavage. In order to determine the challenge dose, serial dilutions were plated in duplicates on 
Brilliance
TM
 CampyCount agar plates (PO 5305A, Oxoid) and incubated for 48 h at 42 °C 
under microaerobic conditions. 
 
3.2. Immunoblot analysis 
An overview of reagents used in immunoblot analysis is given in Table 2. Chicken sera, bile 
and intestinal contents were tested for specific anti C. jejuni N-glycan antibodies using 
“3D5glyc-Bac” and “3D5unglyc” (80 ng/µl loaded of each glycoprotein). The humoral 
immune response against the Salmonella strain was assessed by loading either SKI40 or 
SKI41 whole cell extracts untreated or proteinase K treated (SKI40pk / SKI41pk) (Table 2). 
Protein separation was performed with SDS PAGE, proteins were transferred to a 
polyvinylidenfluorid (PVDF) membrane (IPVH00010, Millipore, Billerica, MA, USA) and 
blocked in 5 % skim milk for 1 hour at room temperature. Blots were washed 3 times with 
TTBS (containing 0.1 % Tween20). Chicken sera were diluted 1:100, bile 1:200 and intestinal 
lavage 1:3 in 1 % skim milk and used in the first incubation step overnight at 4 °C. Blots were 
washed 3 times with TTBS and then incubated for 2 hours with the secondary antibody. For 
positive control an anti mouse antibody was used (see Table 2). After washing, blots were 
developed using enhanced chemilumescent (ECL). Briefly, 1 ml solution A (200 ml 0.1M 
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TRIS-HCl, 50 mg Luminol) was mixed with 0.3 µl 30 % H2O2 and 100 µl solution B (11 mg 
para-hydroxycoumarin acide in 10 ml dimethyl sulfoxide). 
 
3.3. DNA extraction from swabs and tissue samples 
DNA was extracted from caecal contents and cloacal swabs using the QIAamp DNA Stool 
Mini Kit (51504, Qiagen, Hilden, Germany) according to the manufacturer’s instructions. 
Caecal content was weighed before DNA extraction to perform a S. Typhimurium real-time 
PCR quantification. 
DNA from liver and spleen was extracted with the QIAamp DNA Mini Kit (250) (51306, 
Qiagen) following the manufacturer’s guidelines. 
 
3.4. Plasmids 
DNA products were cloned into a pCR2.1 vector using the TOPO TA cloning kit (45-0641, 
Invitrogen, Carlsbad, CA, USA) following the manufacturer’s guidelines. Plasmid isolation 
was performed using the QIagen Plasmid Mini Kit (100) (12125, Qiagen, Hilden, Germany). 
After sequencing (Microsynth, Balgach, Switzerland) the PureYield
TM
 Plasmid Maxiprep 
System (A2393, Promega, Madsion, WI, USA) was used to increase plasmid DNA. Plasmid 
concentration and purity was measured using the spectrophotometer “NanoDrop 2000c” 
(Witec AG, Littau, Switzerland) and diluted in a ten-fold series to establish standard curves 
for the real-time PCRs. The plasmids were named CJ plasmid, CC plasmid and STM plasmid. 
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3.5. Real-time PCR 
3.5.1. Real-time PCR for the detection of S. Typhimurium vaccine strain 
The S. Typhimurium real-time PCR by Park et al. (2008) was used to detect the Salmonella 
vaccine strain SKI40 and SKI41 in organ samples, caecal contents and cloacal swabs. The 
Sal-F (5’-GCGCACCTCAACATCTTTC-3’) and Sal-R 
(5’-CGGTCAAATCCACGTTCA-3’) primers (Mycrosynth) and the SalP probe 
(5’-FAM-ATCATCGTCGACATGCMGB/NFQ-3’) (Applied Biosystems) amplify a 62 bp 
fragment of the STM4497 gene from S. Typhimurium LT2.  
The PCR reaction mixture of a total volume of 25 µl contained: 12.5 µl TaqManUniversal 
PCR MasterMix (2x) (10-pack (10x5ml), 4305719, Applied Biosystems), 400 nM forward 
primer Sal-F, 400 nM reverse primer Sal-R, 200 nM of the probe Sal-P and 10 µl extracted 
sample DNA.  
PCR was carried out on a 7500 Real-Time PCR System with Dell™ Notebook (4351104, 
Applied Biosystems). The threshold value was set to 0.01 with the baseline ranging from 
3-15. 
Quantitation of the Salmonella strains SKI40 and SKI41 in ceacal contents of vaccinated 
chickens was done according to the standard curve approach (User bulletin #2: Relative 
quantitation of gene expression, Applied Biosystems).  
 
3.5.2. Duplex real-time PCR for C. jejuni and C. coli 
To exclude Campylobacter in feed and litter and to prove that day-of-hatch chickens were 
free of Campylobacter, the Campylobacter duplex real-time PCR for the detection of C. jejuni 
and C. coli was performed essentially as described by Hong et al. (2007). This duplex 
real-time PCR was chosen based on its excellent performance in the study by Schnider et al. 
2010. For C. jejuni a 85 bp fragment of the hippuricase gene (hipO-gene, Gen Bank accession 
15 
number Z36940) was amplified, and for C. coli a 81 bp fragment of the ceuE gene, which 
encodes a lipoprotein (ceuE, GenBank accession number X88849) was amplified. The primer 
pair used for C. jejuni detection was: HipO-F (5’-CTGCTTCTTTACTTGTTGTGGCTTT-3’) 
and HipO-R (5’-GCTCCTATGCTTACAACTGCTGAAT-3’) (Microsynth), and the probe 
HipO-P (5’-FAM-CATTGCGAGATACTATGCTTTG-MGBNFQ-3’) (Applied Biosystems, 
Foster City, CA, U.S.A.). The primer pair for C. coli was CeuE-F 
(5’-GATAAAGTTGCAGGAGTTCCAGCTA-3’) and CeuE-R 
(5’-AACTCCACCTATACTAGGCTTGTCT-3’) (Microsynth), and the probe Ceu-P 
(5’-VIC-CTGTAAGTATTTTGGCAAGTTT-MGBNFQ-3’) (Applied Biosystems.)  
Duplex real-time PCR was performed on a 7500 Real-Time PCR System with Dell™ 
Notebook (4351104, Applied Biosystems), using the standard DNA thermal cycle protocol. 
The protocol by Hong et al. (2007) was altered as subsequently described: A total reaction 
volume of 25 µl was used containing 12.5 µl of TaqManUniversal PCR MasterMix (2x) 
(10-pack (10x5ml), 4305719, Applied Biosystems), 300 nM of each primer, 200 nM of each 
probe, and 7 µl extracted DNA from the sample. The data were analysed with the program 
7500 Fast System SDS Software version 1.4.0 (Applied Biosystems). Baseline was set from 3 
to 15, with a threshold adjusted to 0.3 for C. jejuni and C. coli. 
 
3.5.3. Real-time PCR for chicken GAPDH 
As an internal positive control (IPC) for proper working of DNA extraction, an additional 
real-time PCR detecting the chicken glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
pseudo gene was performed (Schybli 2010). The PCR reaction mixture contained 12.5 µl 
TaqManUniversal PCR MasterMix (2x) (10-pack (10x5ml), Order number: 4305719, 
Applied Biosystems), 400 nM of forward primer For_GAPDH 
(3’-GCACGCCATCACTATCTTCCA-5’) and reverse primer Rev_GAPDH 
(3’-TGCCCATTTGATGTTGCTGG-5’), 200 nM of the probe Probe_GAPDH 
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(3’-HEX-TAGCTTTCTCCTCTTGCCACTCCAGAGGATG-TAMRA-5’) and 10 µl 
extracted DNA. The threshold value was set to 0.01 with the baseline ranging from 3-15. 
 
3.6. Chickens 
70 commercial Ross PM3 broiler chickens were obtained from a hatchery (Erb Brüterei AG, 
Aeschlen bei Oberdiessbach, Switzerland) on the day-of-hatch. The broiler breeders and the 
hatchery are free of Salmonella due to a stringent testing regime by order of the Federal 
Veterinary Office (Anonymous, 2009). The parent breeders had a history of being 
Campylobacter-free, tested every 8 weeks using culture. 
Before placing newly hatched chickens into the isolators (390-07-04, LaCalhène, France) they 
were leg ringed. Cloacal swabs were taken and the Salmonella vaccine was administered by 
gavage. Commercial chicken feed (UFA 513, Alleinfutter für Küken mit Kokzidiostatikum, 
UFA AG, Sursee, Switzerland) and water were provided ad libitum. The box liners, feed, and 
bedding wood shavings were cultured to exclude Campylobacter and Salmonella spp. Cloacal 
swabs were tested by C. jejuni / C. coli duplex real-time PCR. Animals were weighted daily 
and at least twice a day checked for clinical symptoms (general condition, diarrhoea, weight 
loss, ruffled feathers and dyspnoea).  
 
3.7. Animal experiments 
3.7.1 Experiment 1.1 
14 one-day old chickens were randomly divided into two equal groups and vaccinated by 
gavage (Table 1). Group 1A received 2.5 x 10
7
 cfu of SKI40 vaccine strain expressing the 
Campylobacter N-glycan. Group 1B was vaccinated with a dose of 3 x 10
7
 cfu of the 
Salmonella SKI41 strain which served as a “backbone” control. Blood was taken from the 
wing vein on day 10, 15 and 20. On day 25 all birds were killed and dissected. Quantitative 
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bacteriology and plasmid stability of the Salmonella vaccine strain was performed with caecal 
contents of 4 animals from each group and confirmed by semi-quantitative Salmonella 
real-time PCR. Bile stored at -20 °C. 
1 g of intestinal contents from the ileum was mixed in 10 ml protease inhibitor cocktail 
cOmplete (04 693 116 001, provided in EASYpack Roche, Rotkreuz, Switzerland). After 
shaking and centrifugation at 10,000 x g for 30 min at 4 °C, the supernatant containing the 
sIgA was collected and stored at -20 °C. 
 
3.7.2. Experiment 1.2 
Immunoblot analysis was performed with sera from groups 1A and 1B and with pooled 
pre-immune sera (see below). The anti N-glycan IgY antibodies in the sera were checked 
against truncated forms of the Campylobacter heptasaccharide by immunoblotting. An 
overview of the different truncated oligosaccharides is given in Table 2. 
 
3.7.3. Experiment 2 
For challenge experiment, chickens were divided into 4 groups (2A-2D) with 14 chickens 
each. 10
7
 cfu of the SKI40 vaccine strain was applied to group 2A. Group 2B served as 
negative control and received sterile PBS at day-of-hatch. Group 2C received 5 x 10
7
 cfu of 
SKI40 at the day-of-hatch and additionally a booster dose, five days later, containing 
1.25 x 10
7
 cfu SKI40. In the backbone control (group 2D) each animal received 4 x 10
7
 cfu 
SKI41 on day one of age and 1.35 x 10
7
 cfu SKI41 on day 5 by gavage. Chickens from group 
2A and 2B were challenged at day 14 with 3 x 10
8
 cfu C. jejuni CC21 ST21, and groups 2C 
and 2D with 5.25 x 10
7
 cfu respectively. During the experiments three chickens of each group 
were killed and dissected on day 18, 23, and 28, and five at the end. Additionally blood was 
taken from the wing vein on day 10, 15, 20, 25 and 30. As described above qualitative 
bacteriology and S. Typhimurium real-time PCR was performed with liver and spleen. 
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Colony counts per gram caecal contents of the vaccine strain SKI40 and SKI41 and the 
challenge strain C. jejuni CC21 ST21 was performed using culture. Sera were used for 
immunoblot analysis and screened for a specific humoral immune response. Bile and 
intestinal contents were also collected to detect sIgA. 
To check the C. jejuni CC21 ST21 stability at the end of the experiment, the challenge strain 
was isolated from caecal contents and typed as described by Wirz et al. (2010). To detect the 
amount of the N-glycan on the Salmonella surface of SKI40 recovered from caecal contents, 
immunoblot analysis was performed using the polyclonal anti N-glycan rabbit serum named 
hR6 (Table 2). 
For all experimental groups, pre-immune serum was obtained and pooled from day-of-hatch 
chicken from the same batch. 
 
3.8. Statistics 
Statistical analysis was performed using the exact Mann-Whitney U Test (Prism_5). P < 0.05 
(two-tailed) was considered to be statistically significant. 
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4. Results 
4.1. Standard curve analysis of the S. Typhimurium, C. jejuni and C. coli real-time PCR  
Linearity persisted over the range of 10
5 
copies to 10
1 
copies for S. Typhimurium, 10
5 
copies 
to 10
1 
copies for C. jejuni, and 10
4 
copies to 10
0 
copies for C. coli. The coefficients of 
determination for the linear regression were: 0.9959, 0.9972 and 0.9992, respectively (data 
not shown). 
 
4.2. Animal experiments 
In all animal experiments feed, bedding and box liners were free from Salmonella and 
Campylobacter. Cloacal swabs of all one-day-old chickens were negative by 
C. jejuni / C. coli duplex real-time PCR.  
 
4.2.1. Experiment 1.1 
Self-limiting diarrhoea was observed from day 2 to 5 in all vaccinated groups. However, none 
of the chickens showed loss of appetite, ruffled feathers, weight loss, or other health 
problems. Upon necropsy, the vaccine as well as the backbone control were detected by 
culture and real-time PCR in liver, spleen and in caecal contents of 14 animals from groups 
1A and 1B (8 x 10
5
 – 3 x 10
7
 cfu/g caecal contents and 6 x 10
5
 – 10
7
 cfu/g, respectively) 
(Table 3).  
Plasmid stability in the vaccine and backbone control was demonstrated (Table 1). A high 
plasmid stability can be deduced in SKI41, 8.7 x 10
6
 – 4.57 x 10
7
 SKI41 cfu per gram caecal 
contents were still carrying the pBR322 plasmid after 25 days (Figure 1). Until the end of the 
experiment, the vaccine Salmonella SKI40 still harboured the pBRpgl3mut. However, the 
spread between plasmid carrying and non-carrying bacteria was pronounced, ranging from 
7 x 10
3
 to 1.7 x 10
7
 SKI40 cfu/g caecal contents (Figure 1).  
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Humoral immune response against the S. Typhimurium vector strain could be detected in all 
sera from chickens of groups 1A and 1B (Figure 2A and 2B). IgY against the 
Campylobacter N-glycan was present in all sera with a marked decrease over time (Figure 
2A). Pooled pre-immune sera from day-of-hatch chickens also showed specific IgY 
against Campylobacter N-glycan (data not shown). No anti heptasaccharide IgM antibodies 
were detected in immunoblots until day 25 in the vaccinated group 1A (Figure 2B). 
 
4.2.2. Experiment 1.2 
In the immunoblot analysis full-length and truncated forms of the Campylobacter 
heptasaccharide (Table 2) were tested as antigens to analyse substrate specificity of IgY. In 
Figure 3A, IgY in sera from one animal reacting with entire and truncated oligosaccharides is 
shown at different time points. hR6, used as a positive control (Table 2), did recognize all 
glycan structures but not the truncated Bac-GalNAc (Figure 3B). The anti N-glycan IgY in 
sera from the chickens showed the same binding pattern as hR6 (Figure 3A and Figure 3B). 
 
4.2.3. Experiment 2 
No significant reduction of the C. jejuni CC21 ST21 challenge strain was detected in 
vaccinated compared to unvaccinated broiler chickens by quantitative culture analysis, with 
the exception of a significant reduction of the caecal C. jejuni load between group 2A 
(vaccine) and group 2B (PBS) at day 35. Anti N-glycan IgY antibodies were present in the 
pre-immune sera (data not shown) and in sera of 4 animals out of 5 from group 2C (vaccine) 
and 2D (backbone) (Table 4) until day 15. Two animals from group 2C and three animals of 
group 2D showed anti N-glycan IgY on day 35 (Table 4 and Figure 4A). In all challenged 
groups, anti heptasaccharide IgM (Table 4) in serum and sIgA in intestine and bile was 
detected on day 35 (Figure 4B and 4C). C. jejuni isolated from caecal contents at day 35 was 
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typed and confirmed to be C. jejuni CC21 ST21. Likewise, the SKI40 vaccine strain was 
confirmed to be carrying the pgl3mut operon using hR6 in immunoblot analysis. 
22 
5. Discussion 
Poultry meat consumption is a known risk factor for human campylobacteriosis (Harris et al. 
1986). Contamination due to Campylobacter on the carcasses during processing at slaughter 
varies between 2 log10-6 log10 cfu (Jacobs-Reitsma et al. 2008). A risk-based modelling on 
human campylobacteriosis calculated the requested decrease in the Campylobacter load in 
intestine of chickens, to achieve reduction of human cases (EFSA 2011). Briefly, the EFSA 
declared that each log10 reduction of the Campylobacter load in chicken intestine would mean 
a 0.64 log10 decrease on the meat. This reduction of the C. jejuni in the chicken intestine 
would result in a campylobacteriosis related public health risk reduction of 48 %. Reaching a 
2 log10 or 3 log10 intestinal load reduction would even reduce the risk of human 
campylobacteriosis by a 76 % or 90 % reduction (EFSA 2011). 
Vaccination against Campylobacter is one strategy to achieve a reduction of the caecal load in 
chickens. Vaccine strategies to immunize broiler chickens against Campylobacter have 
already been explored in different studies (De Zoete et al. 2007, Rice et al. 1997, Wyszynska 
et al. 2004, Buckley et al 2010, Layton et al. 2011), but Campylobacter vaccines are still in 
the development phase and most published studies had a poor reproducibility (EFSA 2011). 
Commensal bacteria and the host immune system interact in the way that sIgA is produced in 
the gut in response to the bacterium in the lumen, with sIgA preventing the bacteria from 
becoming invasive. Bacteremia readily induces a serum IgG response, while no IgA can be 
found in the serum (Macpherson et al. 2000). Concurrent with this knowledge about 
commensals, Campylobacter in chickens is known to dwell in the lumen, mucus and intestinal 
crypts, but does not invade the gut wall. In contrast to intestinal inflammation in 
campylobacteriosis in humans, Campylobacter does not elicit inflammatory responses in 
chickens (De Zoete et al. 2007). 
An oral vaccine should be able to induce first line sIgA response, but also immunology 
memory. Gut mucosal vaccines that are used to prevent human diseases by enteric pathogens 
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generally have mixed success (Pasetti et al. 2011). Oral polio vaccination was as success story 
with a worldwide 99 % decrease in cases since 1988 (WHO 2011a). Vaccines against typhoid 
fever, however, gave different results in different geographic regions. While the oral liquid 
formulation of S.-Typhi Ty21a vaccine was shown to be 77 % effective over 5 years in a trial 
in Chilean school children (Levine et al. 1999, WHO 2011b), the vaccine only showed 
33-53 % protective efficacy in a trial in Indonesia (WHO 2011b). The immunologic basis for 
these differences remains elusive, mostly because the mechanisms of the gut immune system 
are only partially understood (Pasetti et al. 2011). When an enteric pathogen invades the 
human gut, the innate immune system anneals and processes the antigens and, depending on 
the agent, secretes pro-inflammatory signals. The adaptive immune system is responsible for 
specific antigen recognition, specific effector functions and the immunologic memory (Pasetti 
et al. 2011). Cells involved in antigen capture, processing and presentation are foremost 
M-cells and dendritic cells, while B-lymphocytes and T-lymphocytes secret antibodies, 
cytotoxins and fulfil cytotoxic functions (Pasetti et al. 2011). It was shown in humans that 
oral vaccines can elicit a local mucosal sIgA response to prevent attachment and invasion. 
They can neutralise enterotoxins and also induce systemic serum IgG against invasive agents. 
Further cell-mediated immune response and antibody-dependent cellular toxicity response is 
stimulated (Pasetti et al. 2011). 
B-cells that have been primed with the vaccine antigen migrate into the gut-associated 
lymphoid tissue and / or local lymph nodes and subsequently multiply and differentiate. IgA+ 
plasmablasts derived from these B-cells differentiate into polymeric IgA-secreting plasma 
cells in the lamina propria where they secret sIgA. This last differentiation step is mediated by 
activated CD4+ T-helper 2 cells (interleukin 2 (IL-2), IL-5, IL-10), dendritic cells (retinoic 
acid, IL-10, transforming growth factor β (TGF-β), and intestinal epithelial cells (TGF-β, 
IL-6) (Pasetti et al. 2011). 
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Kaiser et al. (2009) stated that one has to be prudent to extrapolate research in the mammalian 
immune system to the avian immune system. In T-cell deficient mice, B-1 cells have been 
shown to be able to produce sIgA in response to commensal bacteria when interacting with 
dendritic cells (Macpherson et al. 2000). The implication of this finding for birds is, however, 
unknown, as birds may altogether use other ways to generate such a response e.g. via the 
bursal lumen (Muir et al. 2000). Chickens clearly have their own cellular and humoral 
immune response and are simply not “feathered mice” (Kaiser et al. 2009) 
 
In chickens, sIgA are the first defence of the mucosal epithelia against enteric pathogens 
(Muir et al. 2000, De Zoete et al. 2007). The chicken intestinal immune system does have an 
antigen-specific sIgA antibody response against enteric pathogens that inhibits attachment 
and colonization of the pathogen. Unfortunately, the innate immune response and the immune 
cells and their secretions are poorly understood in the avian host and fundamental work in this 
area remains to be done (Kaiser et al. 2009). Secretion of intestinal sIgA in the chicken 
against antigens presented in the intestinal surface from Salmonella Typhimurium or 
Campylobacter was demonstrated in different studies (Muir et al. 1998, Noor et al. 1995, 
Widders et al 1996). Nonetheless, vaccines to control intestinal pathogens in chickens do not 
have the expected success (Muir et al. 2000). 
Increase of C. jejuni specific antibodies in chicken and the resulting reduction of bacterial 
shedding was observed during colonization, suggesting an effective immune response against 
these bacteria (De Zoete et al. 2007). In contrast to human infection, chickens however show 
no inflammatory response and tissue damage. Two to three weeks after experimental 
inoculation with Campylobacter, specific serum IgY, IgA and IgM are detectable. sIgA from 
bile and intestine are present at week 3 to 4 (De Zoete et al. 2007).  
In this study we investigated the potential of a S. Typhimurium vaccine strain presenting a 
Campylobacter N-glycan on its surface. 
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As it has been shown that oral and intramuscular infection with S. Typhimurium in different 
inbred chicken lines at day-of-hatch show strain-dependent mortality of 0 % to up to 100 % 
(Bumstead and Barrow 1988), we investigated attenuation of the S. Typhimurium vector 
strain in a first experiment. Sufficient attenuation of the human-derived vaccine strain SKI40 
and SKI41 orally administered to untreated commercial day-of-hatch chicks could be 
demonstrated. The chicks developed a self-limiting diarrhoea from day 2 until day 5 p.i.. The 
bedding was therefore more moist, which may be a problem at a large scale. Upon necropsy, 
Salmonella was detected in liver, spleen and caecal content by culture and real-time PCR. 
Concurrence between culture and real-time PCR results was good. Minor discrepancies can 
be explained with the fact that two different pieces of organs had to be used for culture and 
PCR quantification. Furthermore, faeces is a difficult matrix for real-time PCR analysis. 
Different to carcass rinse, where real-time PCR was always found to be more sensitive than 
culture (Botteldoorn et al. 2008, Schnider et al. 2010), this is not necessarily the case in faeces 
(Inglis and Kalischuk 2004). Groups 1A and 1B had 8 x 10
5
 to 3 x 10
7
 cfu Salmonellae per g 
caecal contents harvested at day 25. Chicks received 2.5 x 10
7
 to 3 x 10
7
 cfu by oral gavage, 
thus it can be deduced that the bacteria were able to colonize the caeca. Immune reaction 
against various proteins and ECA of the SKI40 whole cell extract was demonstrated in all 
inoculated chickens (Figure 2, lane 1). 
 
Although parent breeders of all experiment chickens had a history of being free of 
Campylobacter (tested by faecal bacteriology), specific anti N-glycan IgY were found in 
pooled pre-immune sera. It was observed, that the amount of anti N-glycan IgY antibodies in 
all groups markedly decreased over time from day-of-hatch to day 25 (Figure 2A and 4A). 
Thus, we conclude, that maternal anti Campylobacter antibodies were present in the chickens. 
The occurrence of specific maternal anti Campylobacter antibodies in newly hatched chickens 
is well known and suspected to prevent or at least inhibit natural infection in the first 10 days 
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of the so-called lag-phase (Newell and Fearnley 2003). Maternal IgY are decreasing over the 
first two to three weeks (Myszewski and Stern 1990, Cawthraw et al. 1994). 
According to current knowledge, Bac-GalNAc5-Gluc only exists in Campylobacter and not in 
other bacteria. To prove specificity of IgY detected in large amounts in pre-immune sera and 
thereafter diminishing over time, we tested different entire and truncated forms of the 
Campylobacter heptasaccharide. A decline of maternal IgY binding to all truncated 
glycoproteins is seen (Figure 3A) with exception of the truncated Bac-GalNAc. The positive 
control serum hR6 (produced in rabbits vaccinated with Campylobacter N-glycan expressing 
E. coli) (Figure 3B) and all sera from groups 1A and 1B yielded the same reactivity. 
Consequently, bacillosamine can be excluded as the crucial immunogenic part, because sera 
from groups 1A and 1B did not react with Bac-GalNAc and further reacted with the 
engineered glycan containing GlucNAc instead of bacillosamine.  
Thus, although the parent breeders have a history of being Campylobacter-free, the sera of the 
chicks showed maternal IgY against the N-glycan until day 25. This unexpected result 
discloses the testing regime of the breeders to be insufficient to prove Campylobacter-
freedom. Alternatively, the birds were able to completely clear the bacteria (Achen et al. 
1998, Newell and Fearnley 2003). 
 
The C. jejuni CC21 ST21 used in the challenge experiments was isolated both from caeca and 
neck skin from a slaughter batch of Swiss broilers (Wirz et al. 2010). This strain was chosen 
as it derived from a naturally infected flock and that 18.5 % of poultry-derived C. jejuni 
belonged to CC21 (which comprised of ST 19, 21, 50, 262, 883, 917 and 3988) and thereof 
7.0% to ST 21, rendering those complexes and/or types the predominant in a recent Swiss 
study. Furthermore CC21 is one of the most frequently reported clonal complex in human 
campylobacteriosis (Wirz et al. 2010, Hermans et al 2011). 
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Figure 4 shows that the challenge with C. jejuni provoked a specific humoral immune 
response against the Campylobacter N-glycan in a chicken in group 2C. Likewise, it could be 
detected in all challenged groups (Table 4). Anti heptasaccharide IgM were present in sera at 
day 30. Approximately 20 days after challenge, IgY in sera, sIgA in intestinal lavage and in 
bile were detectable (Figure 4B and 4C). This is in accordance with Baqar et al. (1995), who 
used a Campylobacter killed whole-cell vaccine, and detected specific IgG antibodies at day 
20 p.i. in mice. The vaccine study performed by Wyszynska et al. (2004), using a 
S. Typhimurium expressing the CjaA protein of C. jejuni, showed specific anti CjaA IgY 
rising from week 6 with a peak at week 8 after vaccination in chickens. Despite this late 
specific humoral immune response, the vaccine was shown to reduce the ability of the 
Campylobacter challenge strain to colonize the intestinal tract of the chicken. However, with 
an infective dose of 500 to 800 cfu in humans (Janssen et al. 2008), and a caecal burden of up 
to 10
9
 bacteria per g faeces in chickens (Newell and Fearnley 2003), reduction would have to 
be substantial. In our challenge experiments, using a similar vaccination strategy as 
Wyszynska et al. (2004) (vaccinating on day-of-hatch, use of booster), no significant 
reduction of the C. jejuni caecal load was achieved due to vaccination with the exception of a 
significant reduction of the caecal C. jejuni load between group 2A (vaccine) and group 2B 
(PBS) at day 35 (Figure 5). The Campylobacter N-glycan was nonetheless shown to be 
immunogenic in chicken. Disrupted N-glycosylation in C. jejuni was demonstrated to result in 
impaired colonization of chicken intestinal tract (Szymanski et al. 2002, Karlyshev et al. 
2004), and thus selected as a potent antigen for a Campylobacter vaccine. Moreover, the 
heptasaccharide is conserved among Campylobacter jejuni and coli (Szymanski and Wren 
2005). However, the immune response shown in the chickens in this study only produced a 
specific immune response against naturally presented C. jejuni N-glycan linked to different 
proteins in Campylobacter, and not against the engineered C. jejuni N-glycan linked to the 
lipid A core of the Salmonella vaccine strain. It currently remains elusive, why this vaccine 
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strain could not induce immune reaction against its inbuilt C. jejuni N-glycan. However, all 
immunized chicken reacted against the Salmonella. Further studies need to assess, whether 
the vaccination protocol should be altered (time point of first inoculation and boosters), or 
whether the antigen presentation is adequate, i.e. whether the vaccine Salmonella needs to 
present the C. jejuni N-glycan on proteins or the C. jejuni N-glycan is not present in sufficient 
quantity on the Salmonella surface 
 
6. Conclusion 
The new S. Typhimurium vaccine strain SKI40, expressing the engineered Campylobacter 
N-glycan Bac-GalNAc5-Glc, was shown to be attenuated sufficiently for oral vaccination of 
commercial day-of-hatch broiler chicks and the O-antigen deficient vaccine strain was able to 
colonize the caeca of the chickens. Vaccination of chickens did not lead to a significant 
reduction of C. jejuni colonization in chicken caeca with the herein used antigen presentation 
and / or vaccination protocol. In immunoblot analysis no specific humoral IgM immune 
response against the C. jejuni N-glycan was found after vaccination. However, in the 
challenge experiments IgM, IgY and sIgA against the Campylobacter N-glycan were 
demonstrated after challenge in the vaccinated groups as well as in the control groups. This 
specific immune response is due to Campylobacter challenge on day 14, and not due to 
vaccination. In all sera maternal anti N-glycan IgY antibodies were detectable and declined 
over time until day 25. In a trial with several truncated Campylobacter glycans, the minimal 
antigenic structure was defined to be Bac-GalNAc2.  
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8. Figures and Tables 
Table 1. Bacterial strains and plasmids.
1
 
Bacterial strains Used in / for Source or reference 
SKI40 = Salmonella enterica subsp. enterica serovar Typhimurium SL1344∆wbaP, 
integration of pBRpgl3mut (engineered Campylobacter N-glycan with a GlucNAc 
instead of the bacillosamine) 
Antibiotic resistance on genome: S, T
 
 
animal experiments WO 2010/108682 A1 
"Salmonella enterica presenting 
C. jejuni N-glycan or derivatives 
thereof" 
SKI41 = Salmonella enterica subsp. enterica serovar Typhimurium SL1344∆wbaP, 
integration of pBR322 (backbone without Campylobacter N-glycan) 
Antibiotic resistance on genome: S, T
 
 
animal experiments WO 2010/108682 A1 
"Salmonella enterica presenting 
C. jejuni N-glycan or derivatives 
thereof" 
 
Campylobacter jejuni / Campylobacter coli field strains 
 
real-time PCR confirmed Swiss field isolates 
IVB, University of Zürich, CH 
 
Campylobacter jejuni CC21 ST21 (Ue1655)
 
 
animal experiments, 
challenge strain 
IVB, University of Bern / Wirz 
et al. 2010 
   
Plasmids Used in / for Source or reference 
pBR322 
Antibiotic resistance on plasmid: A
 
 
animal experiments Karin Ilg, Department of 
Microbiology, FIT, CH 
pBRpgl3mut 
Antibiotic resistance on plasmid: A
 
 
animal experiments Karin Ilg, Department of 
Microbiology, FIT, CH 
 
1
Abbreviations (in alphabetical order): A = ampicillin, CC = clonal complex, CH = Switzerland, CRL = community reference laboratory, FIT = federal institute of technology, IVB = institute of 
veterinary bacteriology, NL = The Netherlands, PCR = polymerase chain reaction, S = streptomycin, ST = sequence type, T = tetracycline 
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Table 2. Serum, antibody, protein, glycoprotein and bacterial extract.
1
 
 Abbreviation used in 
manuscript 
Used for Reference / obtained from 
Serum    
rabbit anti C. jejuni N-glycan serum hR6 positive control IB 
(diluted 1:5000) 
Amber 2008, FIT 
    
Antibody    
polyclonal goat anti-mouse IgG HRP conjugated  2
nd
 antibody IB Catalog Number: sc-2005, Santa Cruz Biotechnology Inc., 
(Santa Cruz, CA, USA) 
goat anti-rabbit IgG antibody HRP conjugated  2
nd
 antibody IB Catalog Number: sc-2004, Santa Cruz Biotechnology Inc., 
(Santa Cruz, CA, USA) 
goat anti-chicken IgG (IgY)-Fc antibody HRP 
conjugated 
 2
nd
 antibody IB Catalog Number: A30-104P, Bethyl Laboratories, Inc. 
(Montgomery, TX, USA) 
goat anti-chicken IgM antibody HRP conjugated  2
nd
 antibody IB Catalog Number: A30-102P, Bethyl Laboratories, Inc.  
goat anti-chicken IgA antibody HRP conjugated  2
nd
 antibody IB Catalog Number: A30-103P Bethyl Laboratories, Inc.  
    
Protein    
murine scFv of the anti-His tag antibody 3D5 3D5unglyc IB Lizak et al. 2011 
    
Glycoprotein    
3D5-BacGalNAc5-Glc, naturally occurring 
Campylobacter N-glycan 
3D5glyc-Bac IB Karin Ilg, Department of Microbiology, FIT 
3D5-GlcNAc-GalNAc5-Glc, glycan expressed on 
S. Typhimurium SKI40 
3D5glyc-GlcNAc IB Karin Ilg, Department of Microbiology, FIT 
3D5-Bac-GalNAc5 (truncated form)  IB Karin Ilg, Department of Microbiology, FIT 
3D5-Bac-GalNAc2 (truncated form)  IB Karin Ilg, Department of Microbiology, FIT 
3D5-Bac-GalNAc (truncated form)  IB Karin Ilg, Department of Microbiology, FIT 
    
Bacterial extracts    
whole cell extracts of SKI40 and SKI41 SKI40 and SKI41 IB Karin Ilg, Department of Microbiology, FIT 
proteinase K treated whole cell extracts of SKI40 and 
SKI41 
SKI40pk and SKI41pk IB Karin Ilg, Department of Microbiology, FIT 
1
Abbreviations (in alphabetical order): Bac = bacillosamine, FIT = federal institute of technology, GalNAc = N-Acetylgalactosamine , GlcNac = N-Actelylglucosamine, 
His = polyhistidine, HR = horseradish peroxidase, IB = immunoblot analysis, Ig = immunoglobulin
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Table 3. Detection of Salmonella Typhimurium vaccine strain in liver, spleen and caecal contents of broiler chickens 25 days after oral vaccination 
with 2.5 x 10
7
 cfu SKI40 (group 1A) 3 x 10
7
 cfu SKI41 (group 1B).
1
 
monitored by culture   monitored by real-time PCR  
liver spleen caecal contents  liver spleen caecal contents  
positive/total cfu/g  positive/total cfu/g 
Group 1A (SKI40) 6/7 2/7  5/7 2/7 
Group 1B (SKI41) 4/7 3/7 
8 x 10
5
–3 x 10
7
 
 4/7 1/7 
6 x 10
5
-1 x 10
7
 
 
1
Abbreviations (in alphabetical order): cfu = colony forming units, PCR = polymerase chain reaction, SKI40 = vaccine Salmonella, expressing the Campylobacter N-glycan, 
SKI41 = backbone control, S. Typhimurium = Salmonella enterica subsp. enterica serovar Typhimurium 
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Table 4. Anti Campylobacter N-glycan IgY and IgM kinetics in sera from groups 2A (SKI40 
at day 1), group 2B (PBS at day 1), group 2C (SKI40 at days 1 and 5), and group 2D (SKI41 
at days 1 and 5). All groups were challenged at day 14 with Campylobacter jejuni strain 
CC21 ST21. Blood was taken on day 10, 15, 20, 25, 30 and 35.1 
 
  Sera with anti-glycan IgY 
(positive/total) 
Sera with anti-glycan IgM 
(positive/total) 
Group d 10 15 20 25 30 35 10 15 20 25 30 35 
2A   nd nd nd nd nd nd 0/5 0/5 0/5 0/5 0/5 4/5 
2B   nd nd nd nd nd nd 0/5 0/5 0/5 0/5 1/5 2/5 
2C   4/5 4/5 0/5 0/5 1/5 2/5 0/5 0/5 0/5 0/5 3/5 4/5 
2D   4/5 2/5 0/5 0/5 1/5 3/5 0/5 0/5 0/5 4/5 5/5 5/5 
 
1Abbreviations (in alphabetical order): CC = clonal complex, Ig = immunoglobulin, nd = not done, PBS = 
phosphate buffered saline, SKI40 = vaccine Salmonella, expressing the Campylobacter N-glycan, SKI41 = 
backbone control, ST = sequence type 
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Figure 1. Stability of the pBRpgl3mut plasmid in S. Typhimurium SKI40 and of the pBR322 
plasmid in S. Typhimurium SKI41: recovery from caecal contents on LB agar containing 
antibiotics, 25 days after oral gavage.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Abbreviations (in alphabetical order): cfu = colony forming units, ns = not significant, SKI40 = vaccine 
Salmonella, expressing the Campylobacter N-glycan, SKI41 = backbone control, STA = Luria Bertani agar 
plates containing streptomycin, tetracycline and ampicillin, ST = Luria Bertani agar plates with streptomycin and 
tetracycline 
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Figure 2: Immunoblot analysis using serum from a broiler chicken of group 1A, vaccinated 
with Salmonella Typhimurium vaccine SKI40 expressing the Campylobacter N-glycan. Sera 
were taken on day 10 (a), 15 (b), 20 (c) and 25 (d). 
A IgY detection. B IgM detection. 
Reaction of the sera are shown against Salmonella Typhimurium SKI40 whole cell extract 
(lane 1), lipids and glycolipids of SKI40 after proteinase K treatment (lane 2), unglycosylated 
3D5 protein (lane 3) and glycosylated 3D5 protein (Bac-GalNAc5-Glc, lane 4). The control 
(e) shows 3D5 unglyc (lane 3) and 3D5 glyc-Bac protein (lane 4), with a size of 
approximately 37 kDa. Positions of size markers are indicated on the left. 
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Figure 3: Immunoblot analysis using serum from a broiler chicken of group 1B, vaccinated 
with the Salmonella Typhimurium backbone strain SKI41. Sera were taken on day 10 (a), 15 
(b), 20 (c) and 25 (d). 
A Exclusion of unspecific IgY in sera, using 3D5 protein carrying truncated forms of the 
Campylobacter N-glycan. B Controls for glycan and protein detection, anti N-glycan rabbit 
serum hR6 (e) and polyclonal goat anti-mouse IgG (anti 3D5 carrier protein) (f). 
Reaction of the sera against unglycosylated 3D5 protein (lane 1), and the different truncated 
glycans, 3D5-Bac-GalNAc5-Gluc (2), 3D5-GlcNAc-GalNAc5-Gluc (3), 3D5-Bac-GalNAc5 
(4), 3D5-BacGalNAc2 (5) and 3D5-BacGalNAc (6). Positions of size markers are indicated 
on the left. 
 
A: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B: 
 
 
 
 
37 
49 
64 
82 
2 1 3 4 5 6 
a 
kDa 
37 
49 
64 
82 
1 3 5 6 2 4 
b 
kDa 
82 
37 
d 
6 4 3 2 1 5 
64 
49 
kDa 
37 
1 2 3 4 5 6 
c 
49 
64 
82 
kDa 
49 
37 
kDa e 
64 6 2 1 5 4 3 
49 
64 
37 
f 
6 5 4 3 2 1 
kDa 
43 
Figure 4. Immunoblot analysis using serum from a broiler chicken of group 2C, vaccinated 
and boostered with the Salmonella Typhimurium vaccine SKI40 expressing the 
Campylobacter N-glycan, and challenged with Campylobacter jejuni at day 14. Sera were 
taken on day 10 (a), 15 (b), 20 (c), 25 (d), 30 (e) and 35 (f). 
A IgY detection. B IgM detection. C Secretory IgA detection in intestinal contents (a) and 
bile (b) collected at day 35. 
Reaction of the sera, intestinal contents and bile are shown against unglycosylated 3D5 
protein (lane 1), glycosylated 3D5 protein (Bac-GalNAc5-Glc, lane 2), 
Salmonella Typhimurium SKI40 whole cell extract (lane 3) and lipids and glycolipids of 
SKI40 after proteinase K treatment (lane 4). The controls (A g, B g and C c) show 
3D5 unglyc (lane 1) and 3D5 glyc-Bac protein (lane 2), with a size of approximately 37 kDa. 
Positions of size markers are indicated on the left. 
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Figure 5. Campylobacter jejuni (cfu/g) in caecal contents at different time-points after 
challenge. Groups 2A and 2B were inoculated with the vaccine strain SKI40 or PBS on day 1 
and challenged on day 14 with 3 x 108 cfu C. jejuni. Groups 2C and 2D were inoculated with 
the vaccine SKI40 or the backbone control SKI41 on day 1 and 5 and challenged at day 14 
with 5.25 x 107 cfu C. jejuni.1 
A Groups 2A and 2B. B Groups 2C and 2D. 
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1Abbreviations (in alphabetical order): cfu = colony forming units, n.s. = not significant, SKI40 = vaccine 
Salmonella, expressing the Campylobacter N-glycan, SKI41 = backbone control, ∗ = significant 
n.s. n.s. n.s. n.s. 
∗ n.s. n.s. n.s. 
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